The Year Of The Tiger Looking Strong For IPOs In China Following Sinopharm Success
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Concerns over valuation seem to be doing little to dampen enthusiasm for new Chinese pharmaceutical related stocks and the result is a minefield of opportunities on very shaky ground
You may also be interested in...
After Tough 2011 For Chinese Healthcare IPOs, Policy And Cost Relief Could Be On The Way
China's pharma IPOs didn't meet the hype in 2011. Government action may now ease speculation mania.
China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
SHANGHAI - China's largest private integrated healthcare company Shanghai Fosun Pharmaceutical Co. Ltd. will focus on gaining more market share in China with its branded generic business and branded traditional Chinese medicines, the company said during China's first ever Biotechnology Industry Organization conference held in Shanghai
China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
SHANGHAI - China's largest private integrated healthcare company Shanghai Fosun Pharmaceutical Co. Ltd. will focus on gaining more market share in China with its branded generic business and branded traditional Chinese medicines, the company said during China's first ever Biotechnology Industry Organization conference held in Shanghai